Investing
Eli Lilly’s head of diabetes and obesity unit to retire
© Reuters. FILE PHOTO: Eli Lilly logo is shown on one of the company’s offices in San Diego, California, U.S., September 17, 2020. REUTERS/Mike Blake/File Photo
(Reuters) -Eli Lilly and Co said on Wednesday that the head of its diabetes and obesity division, Mike Mason, will retire by the end of the year after more than three decades with the drugmaker.
Mason oversaw the late-stage development of tirzepatide, Lilly’s potential blockbuster that is sold under the brand name Mounjaro for diabetes and is under U.S. regulatory review for obesity.
Lilly said Patrik Jonsson, president of Lilly USA, will take over Mason’s role.
The company’s shares were down 1% in premarket trading.
Read the full article here
-
Side Hustles6 days ago
Mark Zuckerberg Is Now Second Richest Person in the World
-
Investing6 days ago
Nvidia CEO Jensen Huang: Demand For Blackwell AI Is Insane
-
Side Hustles7 days ago
How to Be Unapologetically You and Why It Matters
-
Side Hustles7 days ago
With AI Magicx, It’s Like Getting an Entire Creative Team in One Money-Saving AI Tool
-
Side Hustles6 days ago
Meta Previews Movie Gen, AI Tools That Turn Dreams to Videos
-
Investing4 days ago
Hurricane Helene Hits Spruce Pine Mine, Quartz Used for Tech
-
Passive Income7 days ago
How AI-Driven Personalization Is Transforming the Retail Industry
-
Investing6 days ago
BCA says investors should fade the real estate rally By Investing.com